The GLP-1R antagonist and the protein kinase A inhibitor (PKI) canceled the antiproliferative effect of Ex-4, which suggests that the Ex-4 reduces prostate cancer cell proliferation due to GLP-1R activation which results in inhibition of ERK-MAPK. This evidence concerns the gene GLP1R and prostate cancer.